Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd. (603392.SH) has released its interim report for the first half of 2026, revealing a net loss attributable to shareholders of 128 million yuan, a narrowing from the prior-year period.

During the reporting period, the company generated total operating revenue of 1.048 billion yuan, reflecting a year-on-year increase of 24.29%. The net loss attributable to shareholders stood at 128 million yuan, which represents an improvement compared to the same period last year. Meanwhile, the net loss after deducting non-recurring gains and losses reached 169 million yuan, also narrowing year-on-year. Basic earnings per share came in at -0.10 yuan.

The growth in operating revenue was primarily driven by the successful market entry and accelerating sales of the nine-valent HPV vaccine following its launch. This led to a notable increase in revenue from the vaccine segment compared to the corresponding period in the previous year.

Furthermore, the reduction in the net loss attributable to shareholders is directly linked to the same factors that fueled the revenue expansion, as the company continues to scale its vaccine commercialization efforts.